Nuclear Medicine & Theragnosis: Key to XXI Spanish Symposium on Neuroendocrine Tumors
- The 21st Symposium of the Spanish Group of Neuroendocrine Tumors (Getne) showcased collaborative advancements in the field, with significant contributions from the Spanish Society of Nuclear Medicine and...
- The recent XXI Symposium of the Spanish Group of Neuroendocrine Tumors (Getne) underscored the necessity of a multidisciplinary, collaborative, and evidence-based approach to advancing the understanding and treatment...
- This year's Getne symposium saw a particularly strong showing from Semnim members, with a notably high number of submissions.
“`html
Spanish Society of Nuclear Medicine & Molecular Imaging Highlights Progress at neuroendocrine Tumor Symposium
Table of Contents
The 21st Symposium of the Spanish Group of Neuroendocrine Tumors (Getne) showcased collaborative advancements in the field, with significant contributions from the Spanish Society of Nuclear Medicine and Molecular imaging (Semnim).
Getne Symposium: A Multidisciplinary Approach to Neuroendocrine Tumors
The recent XXI Symposium of the Spanish Group of Neuroendocrine Tumors (Getne) underscored the necessity of a multidisciplinary, collaborative, and evidence-based approach to advancing the understanding and treatment of neuroendocrine tumors. José L Vercher Conejero, a member of the endocrinology Group of the Spanish Society of Nuclear Medicine and Molecular Imaging (Semnim), emphasized this point, noting the crucial role of collaborative efforts in achieving real progress in this complex pathology.
Semnim’s Strong Presence and Research Impact
This year’s Getne symposium saw a particularly strong showing from Semnim members, with a notably high number of submissions. This reflects the dynamism, scientific quality, and research commitment of professionals within the society. The impact of this research was further demonstrated by Semnim members receiving recognition for their work.
Specifically, one submission from a Semnim member was awarded the prize for best clinical case, a testament to the high caliber of teams and, importantly, the contributions of residents and young researchers within Semnim. This award signifies the growing influence of nuclear medicine and molecular imaging in the diagnosis and management of neuroendocrine tumors.
The Role of Nuclear Medicine and Molecular Imaging in NETs
nuclear Medicine and Molecular Imaging play a critical role in the diagnosis, staging, and monitoring of neuroendocrine tumors. Techniques such as Somatostatin Receptor Scintigraphy (SRS) and Positron Emission Tomography (PET) using Gallium-68 Dotatate are essential for identifying tumor locations, assessing disease extent, and evaluating treatment response. Semnim’s active participation in research and clinical practice is driving innovation in these areas.
| Imaging Technique | Submission in NETs |
|---|---|
| Somatostatin Receptor Scintigraphy (SRS) | Localization of somatostatin receptor-positive NETs. |
| Gallium-68 Dotatate PET/CT | More sensitive detection of NETs, staging, and response assessment. |
| lutetium-177 Dotatate Therapy | Targeted radionuclide therapy for somatostatin receptor-positive NETs. |